Leerink Partnrs issued their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will ...

SAN DIEGO—Ingmar Bruns, the Chief Medical (TASE:PMCN) Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were ...

Officer of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), recently purchased 20,000 shares of the company's common stock. The shares were acquired at a price of $2.2828 each, totaling $45,656.

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oric Pharmaceuticals (ORIC – Research ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Oric Pharmaceuticals (ORIC – Research Report) ...

Story Jan. 28 - Zentalis Pharmaceuticals: In hopes of extending its cash runway through 2026, oncology-focused Zentalis has plans to lay off about 40% of staffers. Release Jan. 27 - Allakos ...